Research
Pharmaxis’ research efforts are focused on discovering new therapies for respiratory diseases.
Our strategy requires the recruitment of high quality dedicated scientists and building a centre of excellence capable of delivering clinical candidates for development.
In addition, we forge alliances with academic and institutional laboratories throughout the world to assist in our endeavours. The products of our research are wholly owned by the company .
Product Pipeline
PXS25/64 - targeting lung fibrosisPXS25 is under development as a new treatment for fibrotic disorders of the lung.
PXS4159 - promising new candidates for asthma
Pharmaxis scientists are discovering new potential medicines for the treatment of asthma and chronic obstructive pulmonary disease.
